Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 8/20 | 0.36 |
| ▸ | CA9 | Q16790 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28947569 | 0.80 | CA1 (0.41) | CA1CA2CA14CA12CA9 | |
| SCHEMBL13978750 | 0.80 | CA2 (0.41) | CA1CA2CA14CA12CA9 | |
| Hydrochloric Acid SCHEMBL28316002 | 0.78 | CA1 (0.39) | CA1CA2CA14CA12CA9 | |
| SCHEMBL3647648 | 0.78 | CA1 (0.39) | CA1CA2CA14CA12CA9 | |
| SCHEMBL7330478 | 0.76 | CA1 (0.35) | CA1CA2CA14CA12CA9 | |
| SCHEMBL25390760 | 0.75 | CA1 (0.37) | CA1CA2CA14CA7 | |
| SCHEMBL3790269 | 0.75 | GCLC (0.37) | CA1CA2CA14CA7 | |
| SCHEMBL19285532 | 0.74 | KMT2A (0.39) | CA2CA14CA9SMN1; SMN2MEN1 | |
| SCHEMBL28063951 | 0.71 | GCLC (0.35) | CA1CA2 | |
| Sulfuric Acid SCHEMBL29010532 | 0.70 | CA1 (0.39) | CA1CA2CA14CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106518850-B | A kind of chemical synthesis process of pimobendan | 青岛农业大学 | 2019-04-09 | — | — | CN | claimed |
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| EP-2539364-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2013-01-02 | — | — | EP | disclosed |
| US-20120021973-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | US | disclosed |
| CN-102223898-A | Peptides for treatment of obesity | NOVO NORDISK AS | 2011-10-19 | — | — | CN | disclosed |
| EP-2370104-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011104378-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| WO-2010060901-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2010-06-03 | — | — | WO | disclosed |
| US-20100056433-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-03-04 | — | — | US | disclosed |
| EP-2104684-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2009-09-30 | — | — | EP | disclosed |
| EP-2101822-A2 | USE OF PEPTIDES IN COMBINATION WITH SURGICAL INTERVENTION FOR THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2009-09-23 | — | — | EP | disclosed |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2009-08-13 | — | — | US | disclosed |
| WO-2008087186-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087189-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087190-A2 | USE OF PEPTIDES IN COMBINATION WITH SURGICAL INTERVENTION FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087187-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087188-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| EP-1907010-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009894-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021973-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | CA1 4462/4885CA2 2853/4885CA14 3242/4885 |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | MC4R, MC3R, GIPR | CA1 4460/4885CA2 3110/4885CA14 2761/4885 |
| US-20100173835-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | CA1 4462/4885CA2 2853/4885CA14 3242/4885 |
| US-20100056433-A1 | Novel Peptides for Use in the Treatment of Obesity | MC4R, MC3R, GIPR | CA1 4460/4885CA2 3110/4885CA14 2761/4885 |
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | CA1 4462/4885CA2 2853/4885CA14 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.